Results 201 to 210 of about 36,269 (231)

Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective. [PDF]

J Mammary Gland Biol Neoplasia
Tuokkola JE, Schwertfeger KL.
europepmc   +1 more source

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation. [PDF]

Oncologist
Kleinhenz F, Pfarr N, Steinhelfer L, Lörsch AM, Bendz H, Friedrich M, Liesenfeld L, Barroux M, Maurer C, Wenzel P, Kestler A, Koppermann ML, Mogler C, Spahn S, Illert AL, Schmid RM, Bitzer M, Lange S.   +17 more
europepmc   +1 more source

Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms. [PDF]

Front Oncol
Choucair K, Chamseddine S, Azmi A, Philip PA.   +3 more
europepmc   +1 more source

FGF family in health and disease. [PDF]

Mol Biomed
Liu X, Jing M, Yang Y, Jin Q, Feng B, Zhang P, Niu C, Hu X, Huang Z.   +8 more
europepmc   +1 more source

High FGFR4 protein expression, but not FGFR1 or FGFR2, predicts poor prognosis in pancreatic ductal adenocarcinoma. [PDF]

BMC Cancer
Braun M, Durślewicz J, Sołek J, Nowicka Z, Zielińska A, Antosik P, Grzanka D.   +6 more
europepmc   +1 more source

From FGFR2 mutations to precision management: a review of prenatal diagnosis and multidisciplinary interventions in apert syndrome. [PDF]

Front Pediatr
Li H, Shen J, Tang M, Wan S, Zhang S.
europepmc   +1 more source

Correction to: The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. [PDF]

Hum Mol Genet
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

The Lancet Gastroenterology and Hepatology, 2021
BACKGROUND Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy.
M. Javle, S. Roychowdhury, R. Kelley, S. Sadeghi, T. Macarulla, K. Weiss, D. Waldschmidt, L. Goyal, I. Borbath, A. El-Khoueiry, M. Borad, W. Yong, P. Philip, M. Bitzer, S. Tanasanvimon, Ai Li, A. Pande, H. Soifer, S. Shepherd, S. Moran, A. Zhu, T. Bekaii-Saab, G. Abou-Alfa   +22 more
semanticscholar   +1 more source

Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

Journal of Clinical Oncology, 2023
4009 Background: Oncogenic FGFR2 alterations (fusions/rearrangements (f/r), amplifications, mutations) represent a broad therapeutic opportunity as they drive multiple solid tumors, particularly cholangiocarcinoma (CCA). However, off-isoform toxicity and
M. Borad, A. Schram, R. Kim, Suneel D. Kamath, V. Sahai, E. Dotan, R. Kelley, M. Ponz-Sarvisé, D. Oh, J. Yachnin, V. Florou, P. Cassier, Joon-Oh Park, C. Liao, Michael Millward, F. T. Ramirez, F. Ricard, A. Hollebecque, V. Subbiah, L. Goyal   +19 more
semanticscholar   +1 more source

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.

Journal of Medicinal Chemistry, 2023
Abnormal activation of fibroblast growth factor receptors (FGFRs) results in the development and progression of human cancers. FGFR2 is frequently amplified or mutated in cancers; therefore, it is an attractive target for tumor therapy.
Lin Ma, Yingying Li, Ruixiang Luo, Yuhan Wang, Jiaqi Cao, Weitao Fu, Bolan Qian, Lei Zheng, Longguang Tang, Xinting Lv, Lulu Zheng, Guang Liang, Lingfeng Chen   +12 more
semanticscholar   +1 more source